Webinars

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Learn more >

Market access for biotechnology

Learn more >

How to build an optimized GVD to populate local HTA/payer templates

Learn more >

Recommendations for driving your journey to digital excellence

Learn more >

The PRMA Healthcheck®: the future of market access in Asia-Pacific

Learn more >

Transform your market access in Asia-Pacific

Learn more >

PRMA Healthcheck® for assets in early stages of clinical development

Learn more >

The evolution of the PRMA Healthcheck® for US payer archetypes

Learn more >

Navigating the updated 2020 ICER value assessment framework

Learn more >

Accelerate the time to patient access with the PRMA Navigator®

Learn more >

EUnetHTA joint clinical assessments: where have we come from and where are we going?

Learn more >

Future proofing for the 2020s market access trends

Learn more >

Managed entry agreements: lessons from EU5

Learn more >

CAR-T therapy: the future begins to take shape

Learn more >

Indication-specific pricing: the obvious solution

Learn more >

Payer perspectives on cell and gene therapies: opportunities and challenges

Learn more >

Market access considerations for CAR-Ts: insights from ASH

Learn more >

Patient-centricity: shaping value generation for HTA and market access

Learn more >

Market access for PD-1 inhibitors: where are we now?

Learn more >

Does 1+1 always equal 2? Valuing combinations

Learn more >

Clarity or confusion: the role of value frameworks in oncology

Learn more >

Please contact us for more information

We respect your privacy. Cookie policy.